These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28237530)

  • 41. [Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population].
    Zhu XD; Zheng A; Wang ZQ; Shao Q
    Zhonghua Nan Ke Xue; 2018 Feb; 24(2):142-146. PubMed ID: 30156074
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Variation in prostate cancer detection rates in a statewide quality improvement collaborative.
    Riedinger CB; Womble PR; Linsell SM; Ye Z; Montie JE; Miller DC; Lane BR;
    J Urol; 2014 Aug; 192(2):373-8. PubMed ID: 24582538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
    Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE
    BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort.
    van Vugt HA; Kranse R; Steyerberg EW; van der Poel HG; Busstra M; Kil P; Oomens EH; de Jong IJ; Bangma CH; Roobol MJ
    Eur J Cancer; 2012 Aug; 48(12):1809-15. PubMed ID: 22406050
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.
    Salami SS; Vira MA; Turkbey B; Fakhoury M; Yaskiv O; Villani R; Ben-Levi E; Rastinehad AR
    Cancer; 2014 Sep; 120(18):2876-82. PubMed ID: 24917122
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
    Ankerst DP; Goros M; Tomlins SA; Patil D; Feng Z; Wei JT; Sanda MG; Gelfond J; Thompson IM; Leach RJ; Liss MA
    Eur Urol Focus; 2019 Jan; 5(1):54-61. PubMed ID: 29422418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
    Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
    Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population.
    Kaplan DJ; Boorjian SA; Ruth K; Egleston BL; Chen DY; Viterbo R; Uzzo RG; Buyyounouski MK; Raysor S; Giri VN
    BJU Int; 2010 Feb; 105(3):334-7. PubMed ID: 19709072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparison of two on-line risk calculators versus the detection of circulating prostate cells for the detection of high risk prostate cancer at first biopsy.].
    Murray NP; Fuentealba C; Reyes E; Jacob O
    Arch Esp Urol; 2017 Jun; 70(5):503-512. PubMed ID: 28613202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
    Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
    Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
    Doan P; Graham P; Lahoud J; Remmers S; Roobol MJ; Kim L; Patel MI
    BJU Int; 2021 Dec; 128 Suppl 3():36-44. PubMed ID: 34374190
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population?
    Lee DH; Jung HB; Park JW; Kim KH; Kim J; Lee SH; Chung BH
    Yonsei Med J; 2013 May; 54(3):665-71. PubMed ID: 23549812
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection.
    Eyre SJ; Ankerst DP; Wei JT; Nair PV; Regan MM; Bueti G; Tang J; Rubin MA; Kearney M; Thompson IM; Sanda MG
    J Urol; 2009 Dec; 182(6):2653-8. PubMed ID: 19836788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
    Ankerst DP; Boeck A; Freedland SJ; Jones JS; Cronin AM; Roobol MJ; Hugosson J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ; Thompson IM
    World J Urol; 2014 Feb; 32(1):185-91. PubMed ID: 22527674
    [TBL] [Abstract][Full Text] [Related]  

  • 56. External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC.
    Poyet C; Wettstein MS; Lundon DJ; Bhindi B; Kulkarni GS; Saba K; Sulser T; Vickers AJ; Hermanns T
    J Urol; 2016 Nov; 196(5):1402-1407. PubMed ID: 27188476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predicting prostate cancer: analysing the clinical efficacy of prostate cancer risk calculators in a referral population.
    Foley RW; Lundon DJ; Murphy K; Murphy TB; Galvin DJ; Watson RW
    Ir J Med Sci; 2015 Sep; 184(3):701-6. PubMed ID: 25843017
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population.
    Wu YS; Fu XJ; Na R; Ye DW; Qi J; Lin XL; Liu F; Gong J; Zhang N; Jiang GL; Jiang HW; Ding Q; Xu J; Sun YH
    Asian J Androl; 2019; 21(6):592-597. PubMed ID: 30924451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study.
    De Nunzio C; Lombardo R; Tema G; Alkhatatbeh H; Gandaglia G; Briganti A; Tubaro A
    Urol Oncol; 2018 Aug; 36(8):364.e1-364.e7. PubMed ID: 29880458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.